Unknown PHASE2 INTERVENTIONAL 1-arm NCT03107962

Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma

PD-1 Blockade With Pembrolizumab in Relapsed or Refractory Natural Killer/T Cell Lymphoma

Sponsor: Mingzhi Zhang

Conditions Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Interventions Pembrolizumab (PD-1 Blocking Antibody)

Updated 6 times since 2017 Last updated: Apr 4, 2017 Started: Feb 19, 2017 Primary completion: Dec 31, 2018 Completion: Dec 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, this trial is ongoing. The trial is conducted by Mingzhi Zhang and has accumulated 6 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
May 2019 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — May 2019 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

May 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Feb 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mingzhi Zhang

Data source: Zhengzhou University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhengzhou, China